BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21978775)

  • 1. Selective and sequential transarterial chemoembolization: survival in patients with hepatocellular carcinoma.
    Antoch G; Roelle G; Ladd SC; Kuehl H; Heusner TA; Sotiropoulos GC; Hilgard P; Forsting M; Verhagen R
    Eur J Radiol; 2012 Sep; 81(9):2290-7. PubMed ID: 21978775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arterial chemoembolization/embolization and early complications after hepatocellular carcinoma treatment: a safe standardized protocol in selected patients with Child class A and B cirrhosis.
    Pietrosi G; Miraglia R; Luca A; Vizzini GB; Fili' D; Riccardo V; D'Antoni A; Petridis I; Maruzzelli L; Biondo D; Gridelli B
    J Vasc Interv Radiol; 2009 Jul; 20(7):896-902. PubMed ID: 19497762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial chemoembolization with additional cisplatin infusion for hepatocellular carcinoma invading the hepatic vein.
    Kim HC; Lee JH; Chung JW; Kang B; Yoon JH; Kim YJ; Lee HS; Jae HJ; Park JH
    J Vasc Interv Radiol; 2013 Feb; 24(2):274-83. PubMed ID: 23369561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma: high hepatitis B viral load and mortality in patients treated with transarterial chemoembolization.
    Yu SJ; Lee JH; Jang ES; Cho EJ; Kwak MS; Yoon JH; Lee HS; Kim CY; Kim YJ
    Radiology; 2013 May; 267(2):638-47. PubMed ID: 23440326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
    Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
    J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma.
    Brown DB; Fundakowski CE; Lisker-Melman M; Crippin JS; Pilgram TK; Chapman W; Darcy MD
    J Vasc Interv Radiol; 2004 Nov; 15(11):1209-18. PubMed ID: 15525739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma.
    Lance C; McLennan G; Obuchowski N; Cheah G; Levitin A; Sands M; Spain J; Srinivas S; Shrikanthan S; Aucejo FN; Kim R; Menon KV
    J Vasc Interv Radiol; 2011 Dec; 22(12):1697-705. PubMed ID: 21983055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
    Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
    J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies.
    Chen BB; Shih IL; Wu CH; Hsu C; Chen CH; Shih TT; Liu KL; Liang PC
    J Vasc Interv Radiol; 2014 Mar; 25(3):371-8. PubMed ID: 24468045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival.
    Grieco A; Marcoccia S; Miele L; Marmiroli L; Caminiti G; Ragazzoni E; Cotroneo AR; Cefaro GA; Rapaccini GL; Gasbarrini G
    Hepatogastroenterology; 2003; 50(49):207-12. PubMed ID: 12630024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study.
    Bargellini I; Sacco R; Bozzi E; Bertini M; Ginanni B; Romano A; Cicorelli A; Tumino E; Federici G; Cioni R; Metrangolo S; Bertoni M; Bresci G; Parisi G; Altomare E; Capria A; Bartolozzi C
    Eur J Radiol; 2012 Jun; 81(6):1173-8. PubMed ID: 21466931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients.
    Yuen MF; Chan AO; Wong BC; Hui CK; Ooi GC; Tso WK; Yuan HJ; Wong DK; Lai CL
    Am J Gastroenterol; 2003 May; 98(5):1181-5. PubMed ID: 12809846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of supraselective transarterial chemoembolization in patients with hepatocellular carcinoma.
    Heinzow HS; Meister T; Nass D; Köhler M; Spieker T; Wolters H; Domschke W; Domagk D
    Scand J Gastroenterol; 2011 Feb; 46(2):201-10. PubMed ID: 20969491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes.
    Yoon SM; Lim YS; Won HJ; Kim JH; Kim KM; Lee HC; Chung YH; Lee YS; Lee SG; Park JH; Suh DJ
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2004-11. PubMed ID: 21621346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes.
    Casadaban LC; Minocha J; Bui JT; Knuttinen MG; Ray CE; Gaba RC
    AJR Am J Roentgenol; 2016 Mar; 206(3):645-54. PubMed ID: 26901023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of transcatheter subsegmental and segmental arterial chemoemobolization using lipiodol for hepatocellular carcinoma.
    Takaki S; Sakaguchi H; Anai H; Tanaka T; Yamamoto K; Morimoto K; Nishiofuku H; Inoue M; Sueyoshi S; Nagata T; Hidaka T; Uchida H; Kichikawa K
    Cardiovasc Intervent Radiol; 2012 Jun; 35(3):544-54. PubMed ID: 21739345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma.
    Rostambeigi N; Dekarske AS; Austin EE; Golzarian J; Cressman EN
    J Vasc Interv Radiol; 2014 Jul; 25(7):1075-84. PubMed ID: 24861664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma.
    Hickey R; Mouli S; Kulik L; Desai K; Thornburg B; Ganger D; Baker T; Abecassis M; Ralph Kallini J; Gabr A; Gates VL; Benson Iii AB; Lewandowski RJ; Salem R
    J Vasc Interv Radiol; 2016 Jun; 27(6):795-802. PubMed ID: 27038686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transarterial chemoembolization for hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt.
    Kang JW; Kim JH; Ko GY; Gwon DI; Yoon HK; Sung KB
    Acta Radiol; 2012 Jun; 53(5):545-50. PubMed ID: 22547388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival with up to 10-year follow-up after combination therapy of chemoembolization and radiofrequency ablation for the treatment of hepatocellular carcinoma: single-center experience.
    Fujimori M; Takaki H; Nakatsuka A; Uraki J; Yamanaka T; Hasegawa T; Shiraki K; Takei Y; Sakuma H; Yamakado K
    J Vasc Interv Radiol; 2013 May; 24(5):655-66. PubMed ID: 23428356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.